Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Precipio's Q3 revenue rises 8% 

By Reuters News


Overview

  • US cancer diagnostics firm's Q3 revenue rose 8% yr/yr to $7.3 mln

  • Product revenue grew 40% yr/yr; pathology revenue up 5% yr/yr

  • Adjusted EBITDA was $0.4 mln, down from $0.5 mln a year earlier


Outlook

  • Company expects pathology business to support future growth and product development


Result Drivers

  • PATHOLOGY BUSINESS - Pathology business provided operational and financial foundation for growth

  • PRODUCT REVENUE GROWTH - Co reported 40% yr/yr increase in product revenue

  • CASH FLOW - End-of-quarter cash balance exceeded $3.5 mln, vs $2.3 mln in Q3-2025


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$7.3 mln


Reuters Recommended Reads

  • Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves

  • Nov 10 - Co-Diagnostics Q3 revenue rises, operating expenses fall 12%

  • Nov 9 - Medical tech firm NeurAxis' Q3 revenue jumps on broader insurance coverage


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.